• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 18, 2015

View Archived Issues

TG seeks twofer in SPA for combo CLL phase III trial

TG Therapeutics Inc. will seek to carry two candidates in its pipeline across the goal line in a single play after reaching agreement with the FDA on a special protocol assessment (SPA) for the design of a phase III study combining TG-1101 (ublituximab), its glycoengineered anti-CD20 monoclonal antibody, and TGR-1202, a glycoengineered once-daily phosphoinositide-3-kinase (PI3K)-delta inhibitor, to treat chronic lymphocytic leukemia (CLL). Read More

Oryzon seeks listing but no cash in Madrid

DUBLIN – Oryzon Genomics SA, one of Spain's flagship biotech firms, is seeking to give the country's sector greater national and international visibility by listing its shares on the main market of the Madrid Stock Exchange (Bolsa de Madrid) in the coming weeks, after which it plans to seek a listing on Nasdaq. Read More

Aerie regains heights after solid Rocket 2 data with IOP-lowering drops

Aerie Pharmaceuticals Inc. – as well as its share price – returned to its previous heights following positive results from the second phase III trial of its triple-action eye drop Rhopressa, which hit its endpoints in lowering intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Read More

Advance into complexity: Gene, cell therapy strides expose work still ahead

BOSTON – Concluding with sessions devoted to regenerative medicine, Biopharm America hosted a panel talk on the state of gene and cell therapy, "a new frontier for all of us," said Frank Borriello, head of search and evaluation for Baxalta Inc., the spinout from Baxter International Inc., of Deerfield, Ill. Read More

Joint ISID symposium shows problems prevail preventing pandemics

SAN DIEGO – The Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) kicks off in full swing Friday, but conference-goers got a primer on pandemic diseases Thursday as ICAAC held a joint symposium with the International Society of Infectious Disease. Read More

Regulatory front

To increase the transparency of its public dockets, the FDA will begin to post comments from individuals beginning Oct. 15. Read More

Financings

Regenxbio Inc., of Washington, priced its IPO of 6.3 million shares at $22 each, above the originally proposed $17 to $19 range. Read More

Stock movers

Read More

Other news to note

Allergan plc, of Dublin, and Gedeon Richter plc, of Budapest, Hungary, said the FDA approved Vraylar (cariprazine) capsules, an atypical antipsychotic, for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for treatment of schizophrenia in adults. Read More

Appointments and advancements

Zosano Pharma Corp., of Fremont, Calif., named Konstantinos Alataris president and chief operating officer, effective Sept. 21. Read More

In the clinic

Hemispherx Biopharma Inc., of Philadelphia, said its board approved a patient assistance program for the open-label AMP-511 study of Ampligen in chronic fatigue syndrome. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 26, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 26, 2025.
  • Deal handshake with coin, chart background

    After axing 95% workforce, Vor bets $4B+ on Remegen’s telitacicept

    BioWorld
    Just a month after laying off 147 employees and announcing plans to mull “strategic alternatives,” Vor Biopharma Inc. reported raising $175 million in private...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • !insulet dexcom CGM

    Pump manufacturers: Patches are the fix for low AID uptake

    BioWorld MedTech
    The rapid adoption of the Omnipod 5 answered a question automated insulin delivery system manufacturers posed for years: with clear health benefits and payer...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe